ADHD Key Stats
- Alcobra Ltd. (ADHD) Submits Protocol for MDX Candidate Phase IIb to FDA Street Insider 04/10 12:31 ET
- Alcobra Ltd. Submits Protocol to FDA for Phase IIb Clinical Study of Metadoxine Extended Release (MDX) in the Treatment of Fragile X Syndrome GlobeNewswire 04/10 12:30 ET
- Relative Strength Alert For Alcobra The Street 04/08 07:58 ET
- ALCOBRA LTD. Financials Yahoo 04/04 13:04 ET
- Nasdaq stocks posting largest volume increases Yahoo 03/28 18:02 ET
- Alcobra Ltd. (ADHD) Shares Unlisted to Nasdaq Global Market Street Insider 03/26 08:21 ET
- Alcobra Announces Shares Uplisted to NASDAQ Global Market GlobeNewswire 03/26 08:00 ET
- Pipeline Update from Alcobra Yahoo 03/24 11:10 ET
- Pipeline Update from Alcobra - Analyst Blog Zacks 03/24 07:10 ET
- Today’s Top Biotech Stories: Prosensa, Medivation, and Alcobra Yahoo 03/18 09:28 ET
ADHD Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Alcobra is up N/A over the last year vs S&P 500 Total Return up 18.46%, Shire up 57.95%, and Questcor Pharmaceuticals up 183.7%.
Balance Sheet View Statement
Pro Ratings for ADHD
Pro Strategies Featuring ADHD
Did Alcobra make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
- Sector: Healthcare
- Industry: Biotechnology
- Headquarters Country: Israel
- Headquarters State/Province: N/A
- Incorporation Country: Israel
- Incorporation State/Province: N/A
- Current Fiscal Year End: December 31, 2014
Alcobra Ltd is a biopharmaceutical company which engaged in the development and commercialization of its proprietary drug, MG01CI, to treat attention deficit hyperactivity disorder.